on Defence Therapeutics Inc. (isin : CA24463V1013)
Defence Therapeutics Inc. Highlights ACCUM Platform for Cancer Treatments
Defence Therapeutics Inc., a Canadian biopharmaceutical company, recently featured its Chief Scientific Officer, Dr. Moutih Rafei, in an interview on Money Talk Radio with Ellis Martin. Dr. Rafei discussed the ACCUM platform, which aims to improve cancer treatments.
Based in Vancouver, Defence Therapeutics specializes in developing innovative immune-oncology vaccines and drug delivery technologies. The company’s proprietary ACCUM technology enhances precision delivery of vaccine antigens or ADCs directly to target cells, potentially increasing treatment efficacy for cancer and infectious diseases.
Listeners can access the full interview on the ABN Newswire website. Defence Therapeutics, listed on multiple stock exchanges including CSE and FSE, continues to advance in the biotechnology field with its clinical-stage developments.
R. E.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Defence Therapeutics Inc. news